Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Rebiotix completes Phase 3 trial enrollment

Investigators have completed enrollment in a phase 3 trial set to investigate RBX2660 from Rebiotix, a therapy that uses the gut microbiota to treat Clostridioides...

| By Kelley Gipson

NanoViricides begins work on coronavirus

Shelton’s NanoViricides is advancing its skin cream for the shingles virus and working on a treatment for the deadly coronavirus. The company, which develops so-called...

| By Kelley Gipson

Shoreline Biome launches DNA isolation product

Shoreline Biome recently unveiled a novel DNA isolation product. Shoreline Rapid Prep is a fast and easy-to-use kit designed for efficient and unbiased isolation of high...

| By Kelley Gipson

Vernon native heads pet cancer vaccine startup

A fascination with viruses has driven Ashley Kalinauskas, who now heads a team of about 10 Torigen employees at UConn’s Cell and Genome Sciences Building...

| By Kelley Gipson

Hyperfine receives 510(k) clearance for portable MRI

A Guilford startup founded by nationally known Connecticut serial entrepreneur Jonathan Rothberg will become the first company to sell a bedside MRI machine after getting...

| By Kelley Gipson

CERC rebrands as AdvanceCT

The Connecticut Economic Resource Center (CERC), the economic- and market-research affiliate of the Department of Economic and Community Development, has rebranded as AdvanceCT. The rebranding...

| By Kelley Gipson

Anteros launch by BMS/BioMotiv uses Yale technology

Bristol-Myers Squibb and BioMotiv have launched Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases....

| By Kelley Gipson

Biohaven scraps anxiety drug; Arvinas expands

Biohaven Pharmaceuticals has pulled the plug on developing its experimental drug for anxiety after the compound performed poorly in a clinical trial. Separately, New Haven...